The oral multitargeted agents, imatinib first, has changed the survival in gastrointestinal stromal tumor (GIST). Sunitinib has been approved for treatment of GIST after disease progression to imatinib. The side effects of Sunitib are well known and are represented mainly by fatigue, HFS, skin rash and diarrhoea. We report a case of ocular toxicity observed in a patient with advanced GIST treated with sunitinib.